Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Metabolomic Profiling Identifies ALL Patients at Risk for MRD and Cancer Relapse

By LabMedica International staff writers
Posted on 07 Nov 2019
Metabolomic profiling of bone marrow from patients suffering from acute lymphoblastomic leukemia was used to identify those who were at high risk of developing minimal residual disease and cancer relapse.

Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the development of large numbers of immature lymphocytes. More...
Symptoms may include feeling tired, pale skin color, fever, easy bleeding or bruising, enlarged lymph nodes, or bone pain. As an acute leukemia, ALL progresses rapidly and is typically fatal within weeks or months if left untreated.

Minimal residual disease (MRD) is the name given to small numbers of leukemic cells (cancer cells from the bone marrow) that remain in the patient during treatment, or after treatment when the patient is in remission (no symptoms or signs of disease). It is the major cause of relapse in cancer and leukemia.

MRD has been identified as being the strongest predictor of relapse in pediatric ALL, but an understanding of the biological pathways underlying early treatment response has not been established. In this regard, investigators at Baylor College of Medicine (Houston, TX, USA) hypothesized that metabolomic profiling of diagnostic bone marrow plasma could provide insights into the underlying biology of early treatment response and inform treatment strategies for high-risk patients.

To test this theory, the investigators analyzed preserved bone marrow samples that had been taken from 155 patients at the time of diagnosis. At the end of their first block of chemotherapy, those patients were evaluated for MRD, a measurement considered the most powerful predictor of relapse.

Results revealed that metabolite set enrichment analysis had identified altered central carbon and amino acid metabolism in MRD-positive patients at a 5% false discovery rate. These findings suggested that metabolomic screening had added value for identifying high risk ALL patients and assigning targeted therapies.

"This research is a demonstration of the power of multidisciplinary collaborations. By bringing together individuals with expertise in epidemiology, pediatric oncology, and leukemia biology, we have made an important step towards identifying a biomarker of treatment response for children diagnosed with ALL, as well as a potential therapeutic target," said senior author Dr. Philip J. Lupo, associate professor of pediatric hematology and oncology at Baylor College of Medicine.

The metabolomic analysis of bone marrow from ALL patients was described in the October 17, 2019, online edition of the journal EbioMedicine.

Related Links:
Baylor College of Medicine


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Host Response Immunoassay Test
MeMed BV
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.